Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Immix Biopharma ( (IMMX) ).
On June 3, 2025, Immix Biopharma, Inc. entered into an At The Market Offering Agreement with Citizens JMP Securities, LLC to offer and sell shares of its common stock at its discretion. This agreement allows the company to raise capital through the sale of shares, with the agent receiving a 3% commission on sales, potentially impacting the company’s financial flexibility and market operations.
The most recent analyst rating on (IMMX) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Immix Biopharma stock, see the IMMX Stock Forecast page.
More about Immix Biopharma
Average Trading Volume: 155,164
Technical Sentiment Signal: Buy
Current Market Cap: $72.48M
For detailed information about IMMX stock, go to TipRanks’ Stock Analysis page.